Abstract
Disruption of a proper regulation of cell proliferation can ultimately cause cancer. Most human B cell malignancies are driven by chromosomal translocations or other genetic alterations which directly affect the function of critical cell cycle proteins, such as cyclins and cyclin-dependent kinases. In addition, the transformation of indolent lymphomas into aggressive malignancies is often accompanied by a loss of tumor suppressors controlling important cell cycle checkpoints. A better understanding of cell cycle deregulations in human tumors has promoted the introduction of a new class of antiproliferative drugs into cancer therapies. These drugs exert their function by specifically blocking important cell cycle proteins. In the present review we discuss how alterations in the cell cycle control contribute to the malignant transformation of B cells. Furthermore, we provide an overview of novel direct and indirect cell cycle inhibitors and their impact on the treatment of patients with B cell lymphomas.
Keywords: Cell cycle regulation, lymphoma, target therapy
Current Drug Targets
Title: Cell Cycle Inhibition in Malignant Lymphoma: Disease Control by Attacking the Cellular Proliferation Machinery
Volume: 7 Issue: 10
Author(s): Ingo Ringshausen, Christian Peschel and Thomas Decker
Affiliation:
Keywords: Cell cycle regulation, lymphoma, target therapy
Abstract: Disruption of a proper regulation of cell proliferation can ultimately cause cancer. Most human B cell malignancies are driven by chromosomal translocations or other genetic alterations which directly affect the function of critical cell cycle proteins, such as cyclins and cyclin-dependent kinases. In addition, the transformation of indolent lymphomas into aggressive malignancies is often accompanied by a loss of tumor suppressors controlling important cell cycle checkpoints. A better understanding of cell cycle deregulations in human tumors has promoted the introduction of a new class of antiproliferative drugs into cancer therapies. These drugs exert their function by specifically blocking important cell cycle proteins. In the present review we discuss how alterations in the cell cycle control contribute to the malignant transformation of B cells. Furthermore, we provide an overview of novel direct and indirect cell cycle inhibitors and their impact on the treatment of patients with B cell lymphomas.
Export Options
About this article
Cite this article as:
Ringshausen Ingo, Peschel Christian and Decker Thomas, Cell Cycle Inhibition in Malignant Lymphoma: Disease Control by Attacking the Cellular Proliferation Machinery, Current Drug Targets 2006; 7 (10) . https://dx.doi.org/10.2174/138945006778559210
DOI https://dx.doi.org/10.2174/138945006778559210 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Phytochemistry and Pharmacognosy of Naturally Occurring Prenyloxyanthraquinones
Current Drug Targets Bioactive Chromone Derivatives – Structural Diversity
Current Bioactive Compounds Berberine as a Promising Safe Anti-Cancer Agent- Is there a Role for Mitochondria?
Current Drug Targets Druggability of Dynamic Protein-protein Interfaces
Current Pharmaceutical Design Circulating Nucleic Acids in Plasma and Serum: Roles in Diagnosis and Prognosis in Diabetes and Cancer
Infectious Disorders - Drug Targets Neuro-Inflammatory Mechanisms in Developmental Disorders Associated with Intellectual Disability and Autism Spectrum Disorder: A Neuro- Immune Perspective
CNS & Neurological Disorders - Drug Targets The Neuroprotective Effect of Ginkgo biloba Leaf Extract and its Possible Mechanism
Central Nervous System Agents in Medicinal Chemistry CelluSpots Arrays as an Alternative to Peptide Arrays on Membrane Supports
Mini-Reviews in Organic Chemistry The Early Results of Vertebral Pathological Compression Fracture of Extra- nodal Lymphoma with HIV-positive Patients Treated by Percutaneous Kyphoplasty
Current HIV Research Protein Z and Ischemic Stroke
Vascular Disease Prevention (Discontinued) Gene Therapy Approaches in an Autoimmune Demyelinating Disease: Multiple Sclerosis
Current Gene Therapy RNA Binding Protein/RNA Element Interactions and the Control of Translation
Current Protein & Peptide Science Azidothymidine is Effective Against Human Multiple Myeloma: A New Use for an Old Drug?
Anti-Cancer Agents in Medicinal Chemistry Anti-Angiogenesis Activities of Dietary Constituents and Health Foods with Potential Anti-Hepatocellular Carcinoma Activity
Recent Patents on Biomarkers LFA-1 on Leukemic Cells as a Target for Therapy or Drug Delivery
Current Pharmaceutical Design Regulatory Mechanisms of Calcineurin Phosphatase Activity
Current Medicinal Chemistry Bypassing Cancer Resistance by Antagonizing “Inhibitor of Apoptosis Proteins” (IAPs)
Current Signal Transduction Therapy New Perspectives in the Pharmacological Potential of Naringin in Medicine
Current Medicinal Chemistry Synthesis and Biological Activity of Quinoxalone Derivatives as BRD4 Bromodomain Inhibitors
Letters in Drug Design & Discovery CDC25A: A Rebel Within the CDC25 Phosphatases Family?
Anti-Cancer Agents in Medicinal Chemistry